Many new discoveries to improve recovery from SCI happen in laboratory studies…
Isn’t it time to invest in treatments for people?
On July 10, 2013, following approval of the JOBS Act over one year ago, the SEC voted to lift the ban on general solicitation. This means that for the first time in nearly 80 years, start-up companies like BioAxone can publicly announce investment opportunities that will accelerate their programs, and accept investments from accredited investors.
What does this mean for Spinal Cord Injury? It means that accredited investors can invest in private companies working on spinal cord injury. This opens up opportunities to accelerate treatments for spinal cord injury, in ways other than giving donations to basic research. Better funding to small companies will help accelerate drug development and bring truly novel and effective treatments to patients.
The new change resulting from the JOBs Act will allow investment in small companies that have the capability to translate research to cures and will accelerate the pace of new treatments.
Every investment will count, and may bring a return both to the patients who need effective medicines, as well as to the risk capital holder.
For information on whether you are an accredited investor, please see SEC.gov.
If you would like additional information on investing in BioAxone, please contact info@bioaxonebio.com.